Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Part D Compliance: Formularies, Subsidies Will Be IG Enforcement Targets

Executive Summary

The HHS Inspector General will be targeting formulary development, measurement of "true out of pocket" spending and employer subsidies in its oversight of the Medicare drug benefit

You may also be interested in...

Medicare Rx Employer Options Are Flexible But Without Windfalls, CMS Says

The Centers for Medicare & Medicaid Services is waiving several Medicare Part D plan requirements for employers to provide maximum flexibility for their participation in the drug benefit

Rx Patient Assistance Programs Encouraged By Medicare Part D Final Rule

Pharmaceutical manufacturer patient assistance programs can be used to cover out-of-pocket costs for Medicare Part D enrollees, CMS says in its final implementing regulations for the drug benefit

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts